Zevra Therapeutics
ZVRA
72 hedge funds and large institutions have $32.6M invested in Zevra Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 30 reducing their positions, and 23 closing their positions.
8% less call options, than puts
Call options by funds: $5.47M | Put options by funds: $5.93M
4.82% less ownership
Funds ownership: 25.74% → 20.92% (-4.8%)
13% less funds holding
Funds holding: 83 → 72 (-11)
28% less capital invested
Capital invested by funds: $45.4M → $32.6M (-$12.8M)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
63% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$2.65M |
| 2 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$1.89M |
| 3 |
E
Ergoteles
New York
|
+$658K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$589K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.38M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.05M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.02M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$929K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$661K |
ZVRA Hedge Fund Activity: Q2 2022 in Review
72 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2022, worth a combined $32.6M — down 28% from $45.4M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ZVRA and 13 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 11 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.65M. The largest seller was BlackRock, cutting an estimated $6.38M.
- 72 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2022, down from 83 in Q1 2022.
- Funds reported $32.6M of Zevra Therapeutics stock for Q2 2022, down 28% quarter-over-quarter.
- 13 funds opened new Zevra Therapeutics positions in Q2 2022 and 23 closed out, a net change of -10 holders.
- The largest Zevra Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.65M added.
- The largest Zevra Therapeutics seller in Q2 2022 was BlackRock, an estimated $6.38M sold.
Based on aggregated 13F filings for Q2 2022.